Market Dynamics The global market for treating Palmoplantar Pustulosis (PPP) exhibited significant strength in 2021 and is poised to maintain a rapid revenue Compound Annual Growth Rate (CAGR) throughout the forecast period. The growth in revenue in the Palmoplantar Pustulosis market is predominantly fueled by factors such as the increasing prevalence of skin diseases and lesions among adults worldwide.

Palmoplantar Pustulosis (PPP) manifests as blister-like lesions on the palms of the hands and the soles of the feet, often accompanied by cracked or reddish, scaly patches. This condition is also referred to as pustulosis palmaris et plantaris, Localized Pustular Psoriasis (LPP), or palmoplantar pustular psoriasis.

Typical symptoms include painful, red skin blisters and pustules, itching, skin cracks, and thick, dry skin. While there is no known cure for palmoplantar pustulosis, various treatments are available to alleviate symptoms.

Get a sample copy of the Palmoplantar Pustulosis Treatment Market report:

Factors Driving Market Revenue Growth:

Opportunities: The absence of standardized treatment protocols for palmoplantar pustulosis presents opportunities for market players to develop new drugs through Research & Development (R&D). Furthermore, increased government funding for research and development of novel medications to treat palmoplantar pustulosis is anticipated to drive market revenue growth over the forecast period.

Geographic Market Scenario:

Region with Largest Market Share: North America is poised to capture the largest revenue share in the global market over the forecast period. In the United States, increasing research endeavors and the rapid adoption of advanced technologies are expected to drive demand for treatment. The presence of key market players and the introduction of advanced products further contribute to revenue growth in this region. For instance, Mylan N.V. launched Hulio in the US in October 2018, expanding its product line to include treatments for Palmoplantar Pustulosis.

Region with Fastest Revenue Growth Rate: The Asia Pacific market is projected to experience a significantly fast revenue CAGR over the forecast period, driven by the increasing incidence of skin diseases and favorable reimbursement policies for biological medications in countries such as India, China, and Brazil. Research and development efforts, along with government initiatives to raise awareness about PPP, are expected to further drive market growth in this region. For instance, in May 2022, Eris Lifesciences entered the dermatology market by acquiring a Mumbai-based dermatology company, Oaknet Healthcare, signaling growth opportunities in the region.

Key Market Trends And Innovations:

Topical medications (typically corticosteroids) and systemic medications remain primary treatment modalities for symptom management, with promising outcomes observed with anti-interleukin-17 drugs and phosphodiesterase type 4 inhibitors.

Advancements in drug development for palmoplantar pustulosis treatment are rapidly evolving. For example, in June 2022, Aristea Therapeutics Inc. announced the dosing of the first subject in the Open-Label Extension (OLE) for its Phase 2b trial of RIST4721 in Palmoplantar Pustulosis (PPP).

Organic and Inorganic Strategies Adopted:

In April 2021, Bristol-Myers Squibb presented significant findings from two pivotal Phase 3 trials evaluating deucravacitinib for the treatment of moderate to severe plaque psoriasis. In October 2020, UCB presented new data on bimekizumab and certolizumab pegol in the treatment of moderate-to-severe plaque psoriasis. In February 2020, Eli Lilly & Company acquired Dermira Inc. for USD 1.1 billion, expanding its dermatology drug portfolio. In May 2018, Taiho Pharmaceutical Co., Ltd. launched TREMFYA Subcutaneous Injection 100mg Syringe (guselkumab) in Japan. Major Companies In The Market Include:

Key Players:

  • GlaxoSmithKline plc
  • Aristea Therapeutics, Inc.
  • AnaptysBio, Inc.
  • Pfizer Inc.
  • AstraZeneca plc
  • Taiho Pharmaceutical Co., Ltd.
  • Sanofi
  • Sandoz International GmbH
  • Novartis AG
  • Almirall, LLC
  • Abbvie Inc.
  • Bristol-Myers Squibb Company
  • UCB S.A.
  • Mylan N.V.
  • Eli Lilly and Company
  • Amgen Inc.

Treatment Outlook (Revenue, USD Million; 2019-2030):

  • First-line therapy
  • Systemic medication
  • Second-line therapy
  • Biologic agent
  • Topical treatment
  • Combination therapy

Route Of Administration Outlook (Revenue, USD Million; 2019-2030):

  • Oral
  • Parenteral
  • Topical

Product Outlook (Revenue, USD Million; 2019-2030):

  • Tablets
  • Creams
  • Ointments
  • Capsules
  • Emollients
  • Injections

Form Outlook (Revenue, USD Million; 2019-2030):

  • Solid
  • Semi-solid
  • Liquid

Distribution Channel Outlook (Revenue, USD Million; 2019-2030):

  • Online
  • Offline

End Use Outlook (Revenue, USD Million; 2019-2030):

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

Regional Outlook (Revenue, USD Million; 2019-2030):

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Benelux
    • Rest of Europe
  • Asia Pacific
    • China

Explore Trending Reports:

Pressure Sensitive Adhesives Market-

Construction Adhesive Market-

Basalt Fiber Market-

Ammonium Nitrate Market-

Roofing Systems Market-

Polyimide Films Market-

Plastic Fasteners Market-

Request a customization of the report:

Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.

About Reports and Data    

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web:

Direct Line: +1-212-710-1370

E-mail: [email protected]

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @

Browse More Latest Reports @

Browse Latest Blogs:

Browse Latest Press Release: